Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.

Anticancer research - 1 Jan 2000

Ecke Thorsten H, Lenk Severin V, Schlechte Horst H, Loening Stefan A

Abstract excerpt

BACKGROUND: Tissue polypeptide antigen (TPA) is a circulating complex of polypeptide fragments from cytokeratins 8, 18 and 19. It is a tumour-related protein. TPA is an indicator of higher cell proliferation. One function of TP53 is the suppression of apoptosis. TP53 mutations are frequently correlated with tumour development in bladder cancer. One function of TP53 is the suppression of apoptosis. We compared TPA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Division
Share to Genes, p53
Share to Luminescent Measurements

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Invasiveness

Share to Reference Values

Share to Sensitivity and Specificity

Share to Statistics, Nonparametric

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 12820330

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.PMID 12820330Read ↗

Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.Semantic proximity Read ↗

[P53 protein gene. Review of the literature and assessment of the prognostic impact of its mutations in bladder tumors].Semantic proximity Read ↗

[Tissue polypeptide antigen and carcinoembryonic antigen in bladder neoplasms].Semantic proximity Read ↗

Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.Semantic proximity Read ↗

Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 yearsSemantic proximity Read ↗

p53 genetic alterations, protein expression and autoantibodies in human colorectal carcinoma: A comparative study.Semantic proximity Read ↗

Serum p53 and bladder cancer: can serum p53 be used as a tumor marker?Semantic proximity Read ↗

[Gene p53 mutation and prognosis in bladder tumors].Semantic proximity Read ↗

Specific-mutational patterns of p53 gene in bladder transitional cell carcinoma among a group of Iraqi patients exposed to war environmental hazards.Semantic proximity Read ↗

Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer.Semantic proximity Read ↗

TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples.Semantic proximity Read ↗

p53 mutations detection in urinary bladder cancer in the Greek population: application of the NIRCA assay.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.